MuscleOnGLPHome/Research/September 22-28, 2026
Weekly research roundup
GLP-1 and muscle research: September 22-28, 2026
This week's papers span drug mechanisms, body composition, and muscle biology relevant to GLP-1-assisted weight loss. Highlights include early-stage research on an ACVR2A inhibitor that may uncouple fat loss from muscle wasting, a hypothesis paper on creatine as a muscle-preservation adjunct during GLP-1 therapy, and a mouse study combining adipose thermogenesis activation with semaglutide. Several papers on aging muscle, prehabilitation, and osteoarthritis also offer useful context for this population.
How to read this
- This roundup is compiled automatically from the abstracts of newly published research and is a neutral summary, not medical advice, not peer review, and not an endorsement. Studies vary in quality and preprints are not yet peer-reviewed. Read the linked source and talk to your clinician before changing anything.
Creatine for glucagon-like peptide-1-associated muscle loss.
This hypothesis paper (not a clinical trial) proposes that the rapid weight loss, reduced energy and protein intake, decreased mechanical loading, and potentially lower physical activity associated with GLP-1-based therapies may create a state of skeletal-muscle bioenergetic vulnerability. The authors suggest creatine supplementation is biologically plausible as an adjunct to support muscle energetics and function in this setting. They explicitly note that no randomized clinical trial has yet directly tested creatine during GLP-1 pharmacotherapy, and call for future trials to evaluate it as part of a multimodal muscle-preservation strategy.
Why it matters: This paper directly addresses the mechanism by which GLP-1 therapy may compromise muscle bioenergetics and frames creatine as a hypothesis-generating candidate adjunct — a question of immediate practical interest for people on these medications.
What this means for you: This adds to the case for discussing multimodal muscle-preservation strategies, including nutritional adjuncts, with a prescribing clinician.
An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.
This mouse study (not a human trial) tested adipose-directed antisense oligonucleotides (ASOs) targeting ZFP423, a transcriptional repressor of brown and beige fat identity, as a complement to semaglutide. In diet-induced obese mice, combining the ZFP423 ASO with semaglutide produced greater weight and fat loss than either treatment alone while preserving lean mass and improving metabolic outcomes including glucose homeostasis and insulin sensitivity. The authors propose adipose thermogenesis activation as a strategy to improve the metabolic quality of GLP-1-driven weight loss.
Why it matters: The study directly addresses lean mass preservation during semaglutide treatment in an animal model, testing a mechanism — adipose thermogenesis — that could in principle complement GLP-1 therapy without sacrificing muscle.
Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.
This cell and biochemistry study (not a human trial) identified fisetin, a natural flavonoid, as a potent inhibitor of ACVR2A — a receptor whose inhibition may help uncouple fat loss from muscle wasting, a concern raised explicitly in the context of GLP-1 receptor agonists. Fisetin showed strong enzymatic inhibitory activity and protected cultured muscle cells (C2C12 myotubes) from Activin A-induced atrophy. However, the compound showed poor pharmacokinetic properties in early testing, limiting its in vivo use; the authors describe it as a lead compound requiring further optimization.
Why it matters: ACVR2A inhibition is an emerging strategy specifically aimed at preserving muscle during GLP-1-driven weight loss, making this early-stage discovery directly relevant to the muscle-loss problem these drugs pose.
Incretin-Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency.
This narrative review paper proposes a hypothesis — not yet validated — that incretin-based therapies (IBTs), including GLP-1 receptor agonists, may induce uncoupling of oxidative phosphorylation (OXPHOS) in mitochondria. The authors cite a case report of acute generalized muscle weakness in a patient with mitochondrial myopathy following tirzepatide exposure as a motivating concern. Preclinical evidence that IBTs activate thermogenic genes and uncoupling proteins is reviewed. The authors call for studies to test whether OXPHOS uncoupling underlies both the weight-loss effects and potential adverse muscle effects of these drugs.
Why it matters: The paper raises a specific, mechanistically grounded concern that GLP-1/GIP therapies may have direct adverse effects on muscle bioenergetics, particularly in individuals with underlying mitochondrial vulnerability.
What this means for you: Worth discussing with a prescribing clinician, particularly for anyone with a personal or family history of mitochondrial or neuromuscular conditions.
Improving Patient Outcomes by Bridging Bariatric and Body Contouring Surgery with Comprehensive Prehabilitation.
This narrative review examines prehabilitation strategies for patients undergoing bariatric and subsequent body-contouring surgery, a population that increasingly includes people on GLP-1 receptor agonists. The authors note that weight-loss pharmacotherapy is associated with reduced fat-free mass, which presents perioperative challenges. Current evidence reviewed suggests that exercise preconditioning, nutritional support, and psychological interventions improve cardiorespiratory fitness and may improve body composition and surgical candidacy. The authors call for standardized protocols and further research.
Why it matters: The paper directly addresses fat-free mass loss associated with GLP-1 pharmacotherapy as a surgical risk factor and reviews exercise and nutrition as mitigation strategies in this specific population.
What this means for you: This is one more reason to discuss exercise preconditioning and nutritional support with a clinician well before any planned surgical procedure.
Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.
This narrative review evaluates the role of GLP-1 receptor agonists and multi-agonists in osteoarthritis (OA) management. The authors note that while these drugs produce substantial pain reduction in trials involving patients with OA and severe obesity, the quality of weight loss matters: reductions in fat mass may be accompanied by bone loss and reduced muscle mass. Patients with sarcopenia or elevated bone resorption are identified as particularly vulnerable to structural deterioration. The authors conclude that obesity pharmacotherapies cannot currently be considered disease-modifying OA treatments and that pain alone should not be the primary outcome measure.
Why it matters: The review explicitly flags muscle mass loss during GLP-1 therapy as a clinically meaningful risk factor for structural joint deterioration in OA patients, a concern that goes beyond cosmetic or metabolic considerations.
What this means for you: This adds to the case for monitoring lean mass and muscle function, particularly for those with joint disease who are using GLP-1 medications for weight loss.
Aging of Skeletal Muscle: From Molecular Mechanisms to Therapeutic Interventions.
This broad review (described as drawing on single-cell, multi-omics, and translational studies) frames skeletal muscle aging as a gradual loss of tissue resilience driven by impaired proteostasis, mitochondrial dysfunction, chronic inflammation, and cellular senescence — not simply a decline in mass. It covers fibro-adipogenic conversion, denervation, and the influence of systemic metabolic signals. Exercise and nutritional optimization are described as the clinical foundation of current therapeutic evidence, with mitochondrial, anabolic, senescence-directed, and regenerative strategies characterized as emerging or investigational.
Why it matters: The mechanistic framework this review provides for muscle loss — particularly the role of proteostasis, inflammation, and nutrition — is directly applicable to understanding and countering the muscle wasting that accompanies GLP-1-driven weight loss, especially in older adults.
What this means for you: This is one more reason to prioritize both resistance training and adequate protein intake as the foundational strategies for maintaining muscle during weight loss.
Prehabilitation for Breast Reconstruction Surgery: A Practical and Evidence-based Guide.
This evidence review of prehabilitation for breast reconstruction surgery identifies sarcopenia and malnutrition as modifiable vulnerabilities associated with higher complication rates and delayed recovery. Interventions reviewed as beneficial across surgical populations include high-protein supplementation, resistance training, immunonutrition, and carbohydrate loading with perioperative glycemic control. The authors note that systematic assessment and multidisciplinary delivery are required, and that prospective studies are needed to define optimal protocols.
Why it matters: The paper reinforces the evidence base for protein optimization and resistance training as pre-surgical preparation strategies relevant to any patient who has experienced muscle loss during pharmacological weight loss prior to surgery.
What this means for you: This adds to the case for discussing prehabilitation — including protein intake and resistance exercise — with a clinician before any planned surgical procedure.
Turn the evidence into a plan
The MuscleOnGLP handbook
These studies point the same direction our guides already put into practice: resistance training and enough protein preserve muscle while you lose weight. The 30-page handbook is the full, cited protocol.
See the handbook — $5 →